--- title: "The IPO Buzz: Avalyn Pharma (AVLN) Priced Upsized IPO at $18 – Top – & Stock Pops" type: "News" locale: "en" url: "https://longbridge.com/en/news/284818412.md" description: "Avalyn Pharma (AVLN) priced its upsized IPO of 16.67 million shares at $18.00, raising $300.06 million. The stock surged to $26.00 in its NASDAQ debut, marking a 44.44% gain. The company focuses on inhaled treatments for rare respiratory disorders, with leading candidates AP01 and AP02 in clinical trials. Despite the successful IPO, Avalyn reported a net loss of $85.2 million with no revenue for the previous year." datetime: "2026-04-30T17:05:03.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284818412.md) - [en](https://longbridge.com/en/news/284818412.md) - [zh-HK](https://longbridge.com/zh-HK/news/284818412.md) --- # The IPO Buzz: Avalyn Pharma (AVLN) Priced Upsized IPO at $18 – Top – & Stock Pops **Avalyn Pharma (AVLN**), **a clinical biotech pioneering inhaled treatments for rare respiratory disorders, priced its upsized IPO of 16.67 million shares at** **$18.00 – the top of its $16.00-to-$18.00 price range – and raised $300.06 million on Wednesday night, April 29, 2026. Shares of Avalyn Pharma (AVLN**) **surged in their NASDAQ debut to open at $26.00 – up $8.00 from the IPO price for a 44.44 percent gain – at 12:23 p.m. EDT today – Thursday, April 30, 2026 – on volume of 813,133 shares. Avalyn Pharma’s stock kept climbing – trading at $27.45 at 12:54 p.m. EDT.** **Morgan Stanley, Jefferies, Evercore ISI and Guggenheim Securities acted as the joint book-runners on Avalyn’s IPO.** **Avalyn Pharma, focused on pulmonary fibrosis, increased its IPO’s size yesterday to 16.67 million shares – up from 11.8 million shares originally – to raise $283.39 million, if priced at the $17.00 mid-point of its range.** **Avalyn Pharma (AVLN), based in Boston, is focused on developing inhaled treatments for progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF).** **In the prospectus, Avalyn Pharma (AVLN) said its leading drug candidate, AP01 , is an inhaled formulation of pirfenidone to treat progressive pulmonary fibrosis (PPF), and its other leading drug candidate, AP02, is an inhaled formulation of nintedanib to treat idiopathic pulmonary fibrosis, or IPF.** **AP01 is currently being evaluated in MIST, a global Phase 2b clinical trial for the treatment of PPF, according to the prospectus.** **AP02 is currently being evaluated in AURA, a global Phase 2 clinical trial for the treatment of IPF.** **“We are also advancing AP03 into a Phase 1 clinical trial. AP03 is a fixed-dose combination of inhaled pirfenidone and nintedanib designed to deliver dual antifibrotic mechanisms with the potential for additive or synergistic benefit,” Avalyn Therapeutics said in the prospectus.** **Avalyn Pharma (AVLN) is not profitable: The company reported a net loss of $85.2 million on no revenue for the 12 months that ended Dec. 31, 2025, according to financial statements in the prospectus.** **(For more information about this company, please check the IPO Calendar and the individual IPO Profile found on the IPOScoop.com website.)** **Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board.** **To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message.** **Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions.** ### Related Stocks - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [TMED.US](https://longbridge.com/en/quote/TMED.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [MS.US](https://longbridge.com/en/quote/MS.US.md) - [JEF.US](https://longbridge.com/en/quote/JEF.US.md) - [EVR.US](https://longbridge.com/en/quote/EVR.US.md) - [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md) - [MS-O.US](https://longbridge.com/en/quote/MS-O.US.md) - [MS-Q.US](https://longbridge.com/en/quote/MS-Q.US.md) - [MS-E.US](https://longbridge.com/en/quote/MS-E.US.md) - [MS-I.US](https://longbridge.com/en/quote/MS-I.US.md) - [MS-L.US](https://longbridge.com/en/quote/MS-L.US.md) - [MS-P.US](https://longbridge.com/en/quote/MS-P.US.md) - [MS-A.US](https://longbridge.com/en/quote/MS-A.US.md) - [MS-F.US](https://longbridge.com/en/quote/MS-F.US.md) - [MS-K.US](https://longbridge.com/en/quote/MS-K.US.md) ## Related News & Research - [14:05 ETLupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution](https://longbridge.com/en/news/286805922.md) - [Eton Pharmaceuticals Adds Another 2026 Launch As It Secures U.S. Rights To IMPAVIDO](https://longbridge.com/en/news/287025596.md) - [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md) - [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md) - [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md)